New biosimilar - Xbryk (denosumab-dssb)

Indicated for 1) solid tumor-associated bone metastases in adult patients; 2) multiple myeloma–associated skeletal-related event prevention in adult patients; 3) unresectable giant cell tumor of bone in adult and adolescent patients with skeletal maturity; and 4) malignant hypercalcemia in adult patients.